ADORA2A and retinopathy of prematurity: Thus, our identification of the hyperoxic phase as the effective therapeutic window, together with selective and robust protection against pathological (but not physiological) angiogenesis and possible cellular mechanisms (i.e. neuronal cell death and endothelial nitric oxide synthase (eNOS) activity), elevates A2AR antagonists as a novel therapeutic strategy for treatment of ROP.